menu
    • menu
    [{"orgOrder":0,"company":"Jounce Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Ipilimumab","moa":"ICOS","graph1":"Oncology","graph2":"Phase II","graph3":"Jounce Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jounce Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Jounce Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Jounce Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Ipilimumab","moa":"ICOS","graph1":"Oncology","graph2":"Phase II","graph3":"Jounce Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jounce Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Jounce Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Jounce Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Termination","leadProduct":"JTX-8064","moa":"LILRB2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Jounce Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Jounce Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Jounce Therapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Jounce Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"JTX-1811","moa":"CCR8","graph1":"Oncology","graph2":"IND Enabling","graph3":"Jounce Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Jounce Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Jounce Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Jounce Therapeutics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Licensing Agreement","leadProduct":"JTX-1811","moa":"CCR8","graph1":"Oncology","graph2":"Preclinical","graph3":"Jounce Therapeutics","amount2":0.81000000000000005,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.81000000000000005,"dosageForm":"","sponsorNew":"Jounce Therapeutics \/ Gilead Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Jounce Therapeutics \/ Gilead Sciences"},{"orgOrder":0,"company":"Jounce Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"JTX-8064","moa":"LILRB2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Jounce Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Jounce Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Jounce Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Jounce Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"JTX-8064","moa":"LILRB2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Jounce Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Jounce Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Jounce Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Jounce Therapeutics","sponsor":"Cowen and Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Public Offering","leadProduct":"JTX-8064","moa":"LILRB2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Jounce Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.059999999999999998,"dosageForm":"intravenous infusion","sponsorNew":"Jounce Therapeutics \/ Cowen and Piper Sandler","highestDevelopmentStatusID":"6","companyTruncated":"Jounce Therapeutics \/ Cowen and Piper Sandler"},{"orgOrder":0,"company":"Jounce Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"JTX-8064","moa":"LILRs","graph1":"Oncology","graph2":"Phase I","graph3":"Jounce Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Jounce Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Jounce Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Jounce Therapeutics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Licensing Agreement","leadProduct":"JTX-1811","moa":"CCR8","graph1":"Oncology","graph2":"IND Enabling","graph3":"Jounce Therapeutics","amount2":0.81000000000000005,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.81000000000000005,"dosageForm":"","sponsorNew":"Jounce Therapeutics \/ Gilead Sciences","highestDevelopmentStatusID":"5","companyTruncated":"Jounce Therapeutics \/ Gilead Sciences"},{"orgOrder":0,"company":"Jounce Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"JTX-8064","moa":"LILRB2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Jounce Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jounce Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Jounce Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Jounce Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"JTX-8064","moa":"LILRB2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Jounce Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jounce Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Jounce Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Jounce Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Pimivalimab","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Jounce Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Jounce Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Jounce Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Jounce Therapeutics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Acquisition","leadProduct":"GS-1811","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Jounce Therapeutics","amount2":0.23000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.23000000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"Jounce Therapeutics \/ Gilead Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Jounce Therapeutics \/ Gilead Sciences"},{"orgOrder":0,"company":"Jounce Therapeutics","sponsor":"Redx Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Merger","leadProduct":"RXC007","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Jounce Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Jounce Therapeutics \/ Jounce Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Jounce Therapeutics \/ Jounce Therapeutics"},{"orgOrder":0,"company":"Jounce Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"JTX-8064","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jounce Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Jounce Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Jounce Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Jounce Therapeutics","sponsor":"Concentra Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Acquisition","leadProduct":"JTX-4014","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Jounce Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Jounce Therapeutics \/ Concentra Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Jounce Therapeutics \/ Concentra Biosciences"},{"orgOrder":0,"company":"Jounce Therapeutics","sponsor":"Redx Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Termination","leadProduct":"RXC007","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Jounce Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Jounce Therapeutics \/ Jounce Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Jounce Therapeutics \/ Jounce Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by Jounce Therapeutics

    Menu

    Jounce Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Jounce Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Jounce Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RXC007

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : Redx Pharma

                            Deal Size : Undisclosed

                            Deal Type : Termination

                            DEALS_DEV arrow-down

                            Termination of Proposed Business Combination of Jounce Therapeutics, Inc. and Redx Pharma plc

                            Details : Under the termination, Jounce Therapeutics will not merge with Redx. The business combination was supposed to aim the development of RXC007, a next-generation selective ROCK2 inhibitor, which is currently being assessed in a Phase 2a study in idiopathic ...

                            Brand Name : RXC007

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            April 03, 2023

                            Lead Product(s) : RXC007

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : Redx Pharma

                            Deal Size : Undisclosed

                            Deal Type : Termination

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Jounce Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Jounce Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vopratelimab,JTX-4014

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Concentra Biosciences

                            Deal Size : $96.4 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Jounce Therapeutics Enters Into Agreement to Be Acquired by Concentra Biosciences for $1.85 in Cash per Share ...

                            Details : Through the merger agreement, Jounce Therapeutics will expand its oncology pipeline by adding JTX-2011 (vopratelimab), JTX-8064 and pimivalimab to its portfolio.

                            Brand Name : JTX-2011

                            Molecule Type : Large molecule

                            Upfront Cash : $96.4 million

                            March 27, 2023

                            Lead Product(s) : Vopratelimab,JTX-4014

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Concentra Biosciences

                            Deal Size : $96.4 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Jounce Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Jounce Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JTX-8064,Pimivalimab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Jounce Therapeutics Announces Results from Pre-Planned Data Review of INNATE Phase 2 Trial of JTX-8064 and Pim...

                            Details : JTX-8064 is a human IgG4 mAb designed to specifically bind to the macrophage receptor Leukocyte Immunoglobulin Like Receptor B2, inhibiting LILRB2 binding with its ligands which may result in reprogramming immune-suppressive macrophages to enhance anti-t...

                            Brand Name : JTX-8064

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            March 16, 2023

                            Lead Product(s) : JTX-8064,Pimivalimab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Jounce Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Jounce Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RXC007

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : Redx Pharma

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            Redx and Jounce Announce Recommended Business Combination

                            Details : Through the business combination, the combined group's priority will be the development of RXC007, a next-generation selective ROCK2 inhibitor, which is currently being assessed in a Phase 2a study in idiopathic pulmonary fibrosis (IPF).

                            Brand Name : RXC007

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            February 23, 2023

                            Lead Product(s) : RXC007

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : Redx Pharma

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Jounce Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Jounce Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GS-1811,Zimberelimab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Gilead Sciences

                            Deal Size : $227.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Gilead to Acquire All Remaining Rights to Potential First-in-Class Immunotherapy GS-1811 From Jounce Therapeut...

                            Details : GS-1811, a potentially first-in-class immunotherapy, is designed to selectively deplete immunosuppressive tumor-infiltrating T regulatory cells in the tumor microenvironment and is in Phase 1 clinical development as a possible treatment for patients with...

                            Brand Name : GS-1811

                            Molecule Type : Large molecule

                            Upfront Cash : $120.0 million

                            December 27, 2022

                            Lead Product(s) : GS-1811,Zimberelimab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Gilead Sciences

                            Deal Size : $227.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Jounce Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Jounce Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pimivalimab,Vopratelimab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Jounce Therapeutics Presents INNATE Phase 1 and SELECT Clinical Trial data at the European Society of Medical ...

                            Details : JTX-8064 is a highly selective and potent inhibitor of myeloid-specific Leukocyte Immunoglobulin Like Receptor B2 (LILRB2, also known as ILT4) with the potential to reverse PD-(L)1 inhibitor resistance.

                            Brand Name : JTX-4014

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            December 08, 2022

                            Lead Product(s) : Pimivalimab,Vopratelimab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Jounce Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Jounce Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JTX-8064,Pimivalimab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Jounce Therapeutics Progresses INNATE Study of JTX-8064 (LILRB2/ILT4 Inhibitor) Monotherapy and Pimivalimab (P...

                            Details : JTX-8064, the first tumor-associated macrophage candidate developed from Jounce’s Translational Science Platform, is a humanized IgG4 monoclonal antibody designed to specifically bind to the macrophage receptor Leukocyte Immunoglobulin Like Receptor B2...

                            Brand Name : JTX-8064

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            October 07, 2021

                            Lead Product(s) : JTX-8064,Pimivalimab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Jounce Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Jounce Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JTX-8064

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Jounce Therapeutics Provides Update on INNATE Study and Discovery Pipeline Expansion, and Provides a Portfolio...

                            Details : A Phase 1 clinical trial, named INNATE, of JTX-8064 as a monotherapy and in combination with pimivalimab (formerly JTX-4014), Jounce’s internal PD-1 inhibitor, is currently enrolling patients with advanced solid tumors.

                            Brand Name : JTX-8064

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            June 23, 2021

                            Lead Product(s) : JTX-8064

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Jounce Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Jounce Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JTX-1811

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Gilead Sciences

                            Deal Size : $805.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Jounce Achieves First Milestone in a License Agreement with Gilead Sciences and FDA Clearance of IND Applicati...

                            Details : JTX-1811, which will be referred to as GS-1811 in Gilead’s pipeline, is a monoclonal antibody created by Jounce and designed to selectively deplete immunosuppressive tumor-infiltrating T regulatory (TITR) cells.

                            Brand Name : GS-1811

                            Molecule Type : Large molecule

                            Upfront Cash : $85.0 million

                            June 15, 2021

                            Lead Product(s) : JTX-1811

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Gilead Sciences

                            Deal Size : $805.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Jounce Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Jounce Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JTX-8064,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Jounce Therapeutics to Present Trial in Progress Posters on the Phase 1 INNATE

                            Details : Two trial in progress posters, on the Phase 1 INNATE clinical trial and the Phase 2 SELECT clinical trial, will be presented at the American Society of Clinical Oncology (ASCO) Virtual Annual Meeting being held June 4-8, 2021.

                            Brand Name : JTX-8064

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            April 28, 2021

                            Lead Product(s) : JTX-8064,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth